Walter Klemp

Oncological drug developers have fierce competition for patients, both in trials and in market. But Moleculin Biotech Inc (NASDAQ: MBRX) rests secure, snugly insulated from the battle. “There’s a reason not a lot of people are playing in the sandbox we’re playing in,”...